Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1424794 | 0.98 | SMN1; SMN2 (0.42) | TPMTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1424790 | 0.88 | ALOX15 (0.48) | TPMTNPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1425679 | 0.86 | ALOX15 (0.46) | TPMTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1425333 | 0.85 | KDM4E (0.46) | TPMTNPC1RAB9AALOX15TSHR | |
| SCHEMBL20888502 | 0.85 | NPC1 (0.41) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1425060 | 0.85 | TPMT (0.48) | TPMTNPC1RAB9AKMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL1425383 | 0.84 | KDM4E (0.45) | TPMTNPC1RAB9AALOX15TSHR | |
| Hydrochloric Acid SCHEMBL1425309 | 0.83 | TPMT (0.47) | TPMTNPC1RAB9AKMT2AALOX15 | |
| SCHEMBL1424792 | 0.83 | NOS3 (0.36) | RAB9AMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1425022 | 0.83 | HTT (0.43) | MEN1KMT2ATSHRHTTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922137-B1 | PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, DYE-ADSORBED ELECTRODE, AND METHOD FOR MANUFACTURING DYE-SENSITIZED SOLAR CELL | FUJIFILM CORP (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-20180186741-A1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-8697732-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8598208-B2 | Pyridine derivatives as S1P1/EDG1 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8367714-B2 | Cannabinoid receptor targeted agent | VANDERBILT UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-02 | — | — | US | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| US-7338651-B2 | Multi-use multimodal imaging chelates | TEXAS TECH UNIVERSITY SYSTEM (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670470-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030209-A1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005421-A1 | Novel Pyridine Derivatives | NFATC1, TPMT, CD47 | TPMT 2/4885NPC1 3600/4885RAB9A 1719/4885 |
| US-20180186741-A1 | A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID | IMPDH2, IMPDH1, GFPT1 | TPMT 49/4885NPC1 3058/4885RAB9A 3354/4885 |
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | TPMT 842/4885NPC1 2252/4885RAB9A 2354/4885 |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | NFATC1, TPMT, CD47 | TPMT 2/4885NPC1 3600/4885RAB9A 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.